Arbutus to Participate in Jefferies Global Healthcare Conference
May 29 2024 - 7:30AM
Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage
biopharmaceutical company leveraging its extensive virology
expertise to develop a functional cure for people with chronic
hepatitis B virus (cHBV) infection, today announced that the
Arbutus management team will present at and host one-on-one
meetings at the following upcoming investor conference being held
in New York:
Jefferies Global Healthcare
Conference: Formal Presentation on June 5, 2024 at 9:30 am
ET
To access the live webcast of the presentation,
please visit: https://investor.arbutusbio.com/events-presentations.
An archived replay of the webcast will be available on the Arbutus
website for a limited time after the event.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is
a clinical-stage biopharmaceutical company leveraging its extensive
virology expertise to identify and develop novel therapeutics with
distinct mechanisms of action, which can be combined to provide a
functional cure for patients with chronic hepatitis B virus (cHBV).
We believe the key to success in developing a functional cure
involves suppressing HBV DNA, reducing surface antigen, and
boosting HBV-specific immune responses. Our pipeline of internally
developed, proprietary compounds includes an RNAi therapeutic,
imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran
has generated meaningful clinical data demonstrating an impact on
both surface antigen reduction and reawakening of the HBV-specific
immune response. Imdusiran is currently in three Phase 2a
combination clinical trials. AB-101 is currently being evaluated in
a Phase 1a/1b clinical trial. For more information, visit
www.arbutusbio.com.
Contact Information
Investors and MediaLisa M. CaperelliVice
President, Investor RelationsPhone: 215-206-1822Email:
lcaperelli@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Jul 2024 to Aug 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Aug 2023 to Aug 2024